{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:28:49Z","timestamp":1785796129219,"version":"3.56.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background and Purpose<\/jats:title><jats:p>Previous studies have found tacrolimus to be a favorable drug for treating different types of myasthenia gravis (MG), but few have focused on very-late-onset MG (VLOMG). This study evaluated the efficacy and safety of tacrolimus for VLOMG therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective single-center cohort study of 70 patients with VLOMG (onset \u226565 years) who visited Peking University First Hospital in 2019. Participants were divided into the tacrolimus (Tac) group and the control group based on tacrolimus usage. We further divided the Tac group into patients treated without corticosteroids and with corticosteroids. Sociodemographic features, clinical profiles, and outcomes were compared between different therapies and further analyzed by multivariate regression. Details of tacrolimus treatment, comorbidities, and adverse drug reactions (ADRs) were described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 70 patients, the median (interquartile range) age at onset was 71 (68\u201377) years, and the follow-up duration was 27 (27-29) months. Most patients were types I (28%) and III (40%) according to the MG Foundation of America (MGFA) classification. In the Tac group, tacrolimus treatment was maintained for 36 (27-38) months. The dosage at the final evaluation was 1.0 (1.0\u20131.75) mg\/day, and the last blood concentration test was 4.25 (2.85\u20135.7) ng\/ml. A total of 43% reached remission, and 37% improved based on MGFA postintervention status (MGFA-PIS). For the 9 patients, newly diagnosed at enrollment within this group, MG activities of daily living (MG-ADL) decreased significantly from 3 (2-5) to 2 (1-2) (<jats:italic>p<\/jats:italic>= 0.041). Regarding the 13 patients, coadministering Wuzhi capsules the tacrolimus concentration increased from 2.75 (1.4\u20133.8) ng\/ml to 5.95 (5.1\u20137.0) ng\/ml (<jats:italic>p<\/jats:italic>= 0.012). No significant differences in outcomes were observed between tacrolimus treatment without and with corticosteroids or between the Tac group and the control group. A total of 93% had at least one comorbidity. ADRs related to tacrolimus emerged in 25% (9\/36) of patients, most of which were not serious and reversible.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Tacrolimus is effective and safe in treating VLOMG. Tacrolimus monotherapy without corticosteroids can be used as an initial and maintenance treatment for VLOMG. Wuzhi capsules work well in elevating tacrolimus concentrations in this population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.843523","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T18:57:03Z","timestamp":1648666623000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Safety of Tacrolimus Therapy for a Single Chinese Cohort With Very-Late-Onset Myasthenia Gravis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yiming","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"55","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41582-020-0345-3","article-title":"New insights into very-late-onset myasthenia gravis","volume":"16","author":"Barnett","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mus.27369","article-title":"Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis","volume":"62","author":"Vijayan","year":"2021","journal-title":"Muscle Nerve"},{"key":"B6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J Neurol Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.lanwpc.2020.100063","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health Western Pacific."},{"key":"B8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","article-title":"A study of comorbidities in myasthenia gravis","volume":"120","author":"Misra","year":"2020","journal-title":"Acta Neurol Belg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40266-015-0297-2","article-title":"Treatment of myasthenia gravis in the aged","volume":"32","author":"Alkhawajah","year":"2015","journal-title":"Drugs Aging."},{"key":"B10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","article-title":"Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis","volume":"11","author":"Zhao","year":"2011","journal-title":"Int Immunopharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3349\/ymj.2019.60.7.633","article-title":"Long-term safety and efficacy of tacrolimus in Myasthenia gravis","volume":"60","author":"Kim","year":"2019","journal-title":"Yonsei Med J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2020.594152","article-title":"Favorable effects of tacrolimus monotherapy on myasthenia gravis patients","volume":"11","author":"Fan","year":"2020","journal-title":"Front Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther Adv Neurol Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of myasthenia gravis\u2014a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9138548","article-title":"Tacrolimus as single-agent immunotherapy and minimal manifestation status in nonthymoma Myasthenia gravis","volume":"2021","author":"Duan","year":"2021","journal-title":"J Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.clineuro.2018.07.023","article-title":"Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV myasthenia gravis","volume":"173","author":"Zhao","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2217\/pgs-2018-0116","article-title":"Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach","volume":"20","author":"Han","year":"2019","journal-title":"Pharmacogenomics."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.2147\/NDT.S319500","article-title":"Clinical evaluation of the efficacy and safety of co-administration of wuzhi capsule and tacrolimus in adult Chinese patients with myasthenia gravis","volume":"17","author":"Peng","year":"2021","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.phymed.2013.12.006","article-title":"Effect of Tacrolimus on the pharmacokinetics of bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) and the potential roles of CYP3A and P-gp","volume":"21","author":"Qin","year":"2014","journal-title":"Phytomedicine."},{"key":"B20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: association of british neurologists' management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ene.13189","article-title":"Adequate tacrolimus concentration for myasthenia gravis treatment","volume":"24","author":"Kanai","year":"2017","journal-title":"Eur J Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J Neurol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve."},{"key":"B26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/mus.25720","article-title":"The utility of a single simple question in the evaluation of patients with myasthenia gravis","volume":"57","author":"Abraham","year":"2018","journal-title":"Muscle Nerve."},{"key":"B27","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","article-title":"Estimating an EQ-5D-5L value set for China","volume":"20","author":"Luo","year":"2017","journal-title":"Value Health."},{"key":"B28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.47102\/annals-acadmedsg.V38N8p714","article-title":"A practical guide for multivariate analysis of dichotomous outcomes","volume":"38","author":"Lee","year":"2009","journal-title":"Ann Acad Med Singapore."},{"key":"B29","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/ene.13836","article-title":"EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis","volume":"26","author":"Barnett","year":"2019","journal-title":"Eur J Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jocn.2021.07.020","article-title":"Evaluation of outcome measures for myasthenia gravis subgroups","volume":"91","author":"Luo","year":"2021","journal-title":"J Clin Neurosci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/cns.13468","article-title":"Immunotherapy choice and maintenance for generalized myasthenia gravis in China","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci Therap."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/nyas.13567","article-title":"Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?","volume":"1413","author":"Rinaldi","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.trre.2013.12.004","article-title":"Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment","volume":"28","author":"Wissing","year":"2014","journal-title":"Transplant Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1111\/j.1600-6143.2008.02430.x","article-title":"The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer","volume":"8","author":"Chamie","year":"2008","journal-title":"Am J Transp."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: an update","volume":"10","author":"Sheikh","year":"2021","journal-title":"J Clin Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/0194599820947001","article-title":"Predictors of complications occurrence associated with emergency surgical tracheotomy","volume":"164","author":"Jotic","year":"2021","journal-title":"Otolaryngol Head Neck Surg."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.843523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:07:11Z","timestamp":1675123631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.843523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":38,"alternative-id":["10.3389\/fneur.2022.843523"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.843523","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"article-number":"843523"}}